Form 4: Elanco Director Anand Kapila Acquires Shares
Insider Transaction Report
Elanco Animal Health Inc. reports that Director Anand Kapila acquired shares through grants of deferred and restricted stock units.
Summary
- Director Anand Kapila received a grant of 4,678 deferred stock units as a pro-rated annual equity award.
- Director Anand Kapila also received a grant of 12,196 restricted stock units as an annual equity award.
- These awards were granted to non-employee members of the Issuer's Board of Directors.
- The transactions occurred on May 21, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine equity awards to a director and does not contain new financial information or strategic shifts.
Positives
- Director Anand Kapila received equity awards, indicating continued alignment with the company's performance.
- The grants are part of the annual equity award program for non-employee directors.
Future Outlook
This filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that equity awards to directors are a common practice in the animal health industry to incentivize long-term performance and align management interests with shareholders.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Kapila K. Anand granted power of attorney to Shiv ONeill, Robert M. VanHimbergen, Megan Y. Brady, Amy C. Seidel, and Amra Hoso to execute SEC filings on their behalf. | 05/21/2026 | Standard procedure for facilitating timely and accurate SEC filings by individuals who may not be able to personally sign each document. |
Stakeholder Impact
- Shareholders: The equity awards to directors reinforce alignment of interests, which can be viewed positively.
- Employees: This filing does not directly impact employees.
Key Dates
| Date | Description |
|---|---|
| 05/21/2026 | Earliest transaction date and date of equity awards. |
| 05/26/2026 | Date of signature for the filing. |
Keywords
Elanco Animal Health, ELAN, Form 4, SEC Filing, Director Equity Award, Deferred Stock Units, Restricted Stock Units, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.